CORRELATION BETWEEN APOB/APOAI RATIO AND DYSLIPIDEMIA IN INDIAN CHRONIC HEART FAILURE PATIENTS

Dr. Rohit Sane, Dr. Gurudatta Amin, Dr. Snehal Dongre and *Dr. Rahul Mandole

ABSTRACT

Background: Ratio of apolipoprotein-B (apoB) and apolipoprotein-AI (apoAI) is found to be a strong predictor for cardiovascular diseases, including chronic heart failure (CHF). The debatable relationship between apoB/apoAI and other lipid parameters has not been explored in Indian CHF patients. Hence, we evaluated the correlation between apoB/apoAI and lipid parameters in Indian CHF patients. Methodology: This retrospective study was conducted using data of CHF patients who visited Madhavbaug clinics in India, between July-December 2018. The parameters assessed under lipid profile on the collected venous blood from patients included serum total cholesterol (TC), serum triglycerides (TG), serum low-density lipoproteins (LDL), serum high-density lipoproteins (HDL), serum very-low density lipoproteins (VLDL), serum apoAI and apoB. The apoB/apoAI ratio was calculated and then correlation with other lipid parameters was assessed using Pearson correlation coefficient test. Results: Of the 147 included CHF patients, majority were males (N=109,74.15%) with a mean age of 59.15+10.28 years. The correlation coefficient (R) was found to be 0.41 and 0.24 respectively between apoB/apoAI ratio and serum TC as well as apoB/apoAI ratio and serum TG, which were statistically significant (p<0.05). Correlation between apoB/apoAI ratio and serum HDL was found to be indicative of inverse correlation, but this was not significant statistically (p>0.05). Correlation between apoB/apoAI ratio and serum LDL (R=0.39), serum VLDL (R=0.24) as well as LDL/HDL ratio (R=0.25) were all found to be positive and these findings were statistically significant (p<0.05). Conclusion: Raised apoB/apoAI ratio was found to be significantly correlated with dyslipidemia in the Indian CHF patients.

Keywords: Dyslipidemia, Apolipoprotein B, Apolipoprotein AI, Lipoproteins, Chronic Heart Failure.